Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lisa Hang(National Comprehensive Cancer Network), Yaron Gesthalter(UCSF Helen Diller Family Comprehensive Cancer Center), Suzanne McGettigan(University of Pennsylvania), Julie R. Brahmer(Johns Hopkins University), Vlad G. Zaha(Southwestern Medical Center), Bryan J. Schneider(Georgetown University), Theresa Medina(University of Colorado Cancer Center), Pradnya D. Patil(Cleveland Clinic), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Marianne Davies(Smilow Cancer Hospital), Aparna Hegde(University of Colorado Cancer Center), Olalekan O. Oluwole(Vanderbilt University), Jordan P. McPherson(University of Utah), Philippe Armand(Harvard University), Amro Elshoury, Nisha Mohindra(Fox Chase Cancer Center), Sandip Pravin Patel(University of California San Diego), Mabel Ryder(Mayo Clinic in Arizona), Amaka Achufusi(University of Wisconsin Carbone Cancer Center), Alissa Marr(Susan Thompson Buffett Foundation), Meghan Berkenstock(Johns Hopkins University), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Anthony J. Olszanski(Fox Chase Cancer Center), Tianhong Li(VA Northern California Health Care System), Melissa G. Lechner(University of California, Los Angeles), Benjamin H. Kaffenberger(The Ohio State University Wexner Medical Center), Lihua E. Budde(City Of Hope National Medical Center), Saurin Chokshi(St. Jude Children's Research Hospital), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Sunil Reddy(Cancer Institute (WIA)), Megan Lyons(Yale University), Scott Shofer(Cancer Institute (WIA)), Bianca Santomasso(Georgetown University), Mary A. Dwyer(National Comprehensive Cancer Network), Michael D. Jain(Moffitt Cancer Center)
Cited by 416
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k